Navigation Links
Kinex Announces First Patient Dosed in Phase Ib Study of Oraxol, an Orally Dosed Paclitaxel
Date:10/28/2013

BUFFALO, N.Y., Oct. 28, 2013 /PRNewswire/ -- Kinex Pharmaceuticals today announced that the first patient has been dosed in its Phase Ib Oraxol study.  Oraxol allows for oral delivery of paclitaxel when combined with Hanmi Pharmaceutical's absorption enhancer, HM30181A.  This trial is being conducted in the United States.  Oraxol is in PII studies in Korea and will commence a PI in New Zealand in 2014.  Kinex has global development and commercialization rights for Oraxol, excluding Korea, Japan and India that are owned by Hanmi, and New Zealand and Australia which were recently licensed to Zenith Technology Corporation.

This single arm, dose escalation study is designed to bridge the safety, pharmacokinetics and tolerability of Oraxol that was observed by Hanmi Pharmaceutical in their Korean trials.  Kinex expects to enroll 25-35 patients.  Clinical studies of Oraxol to date suggest that this potent, oral version of paclitaxel will impact a broad spectrum of cancers.

Dr. Wen Wee Ma, MBBS, Assistant Professor at Roswell Park Cancer Institute and Primary Investigator for the Phase Ib trial stated, "Our team at Roswell Park has broad experience developing taxane based compounds.  Oraxol is an exciting program for us as it offers many important potential benefits to patients and clinicians including tolerability, convenience of oral administration and increased efficacy.  The design of this trial was guided by the predictive PK of Oraxol developed by Kinex and Roswell Park and we are extremely excited by its launch."

"The initiation of Kinex's Phase Ib is another important step in the Kinex /Hanmi collaboration," said Dr. Lyn Dyster, Senior Vice President of Operations. "The trial is des
'/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Hanmi Pharmaceuticals to Assign the Rights to Five New Territories to Kinex as Part of the Orascovery Program Strategic Plan
2. Dr. David Hangauer, Chief Scientific Officer and Co-Founder, commits his career to Kinex Pharmaceuticals
3. Kinex Receives Research Support from the Hong Kong Innovation and Technology Commission (ITC)
4. Kinex Announces that the US FDA Allows their IND for Oraxol, an Oral Form of Paclitaxel that is in Phase II Clinical Trials in Korea, to Begin Clinical Trials in the US
5. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
6. Kinex Announces that the US FDA Allows their IND to Begin KX02 Clinical Trials
7. Kinex Pharmaceuticals and Zenith Technology Corporation announce the execution of a collaborative licensing agreement
8. Kinex Pharmaceuticals Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Societys 2013 Honoree for its Cuisine for a Cure event
9. Hanmi and Kinex Announced Korean FDA Allowance of the KX01 IND Application
10. Kinex Pharmaceuticals Appoints Mr. Patrick Gallagher Vice President of Business Development and Investor Relations
11. Kinex Pharmaceuticals Receives Substantial Strategic Investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Boston Scientific ... participate in the 2014 Credit Suisse Annual Healthcare Conference ... , AZ.  Dan Brennan , executive vice ... about the company beginning at approximately 8:00 a.m. PT ... A live webcast of the presentation and question and ...
(Date:10/30/2014)... 2014  Nektar Therapeutics (Nasdaq: NKTR ) ... ended September 30, 2014 on Thursday, November 6, 2014, ... Robin , president and chief executive officer, will host ... 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... audio-only Webcast of the conference call can be accessed ...
(Date:10/30/2014)...   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... company, today announced financial results for the third ... important corporate, commercial, regulatory and clinical development updates ... very pleased with the continued momentum and strong ... portfolio this quarter, especially the XIAFLEX franchise, which ...
Breaking Medicine Technology:Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22
... in Combination with CRESTOR (rosuvastatin calcium) Improved LDL, HDL ... ... SEATTLE, May 31 New Phase III data showed,that in ... AstraZeneca,s CRESTOR(R) (rosuvastatin,calcium) led to greater improvements than the corresponding ...
... Annual Meeting -, SOUTH SAN FRANCISCO, ... Pharmaceuticals, Inc. (Nasdaq: PARD ), a ... safety and,efficacy data from its ongoing Phase ... docetaxel and prednisone, the standard of care ...
Cached Medicine Technology:Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids 2Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids 3Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids 4Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer 2Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer 3Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer 4
(Date:10/30/2014)... , A mathematical model developed by NIH grantees predicts ... to prevent HIV infection via vaginal sex, whereas just ... infection via anal sex. This finding helps explain why ... PrEP, in women failed to show efficacy. Participants in ... of Truvada and tenofovir (another antiretroviral) for HIV prevention ...
(Date:10/30/2014)... October 30, 2014 Graphics, coding, typography ... synonymous with the craft of web design and require ... Yet a simpler solution to create a website can ... videos, contact information, customer reviews and Facebook posts all ... "It is the next evolution of how a business ...
(Date:10/30/2014)... 30, 2014 Five months after their ... Street LLC announces new branding and a website to ... . After David Mepham’s promotion to name partner earlier ... website to include Mepham’s name and better reflect their ... mediation firm, the decision to implement new branding reflects ...
(Date:10/30/2014)... Radio listeners who indicate use of four ... of traditional radio commercials and have overwhelmingly endorsed custom ... a purchasing decision. , Those are some highlights from ... radio marketing company CRN International. The research is now ... respondents who indicated they have purchased or considered purchase ...
(Date:10/30/2014)... Thompson HealthDay Reporter WEDNESDAY, ... Liberia -- one of three West African nations ravaged by ... said Wednesday. Dr. Bruce Aylward, WHO,s assistant director general, ... in Liberia and no increase in laboratory-confirmed cases. He said ... the epidemic may be making some progress, The New ...
Breaking Medicine News(10 mins):Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3
... , , WICHITA, Kan., ... public that late-term abortionist LeRoy Carhart will not be granted a transfer ... hours after Operation Rescue launched a pet i ... that Wesley Medical Center deny late-term abortionist LeRoy Carhart hospital or transfer ...
... RIVER EDGE, N.J., Aug. 14 Nephros, Inc. (OTC Bulletin Board: NEPH) announced today ... Recent Highlights , , , ... , Issued four new patents , ... , "2009 has continued to be a productive year for Nephros," said ...
... , , , , ... US: ADL), a U.S.-based pharmaceutical company with major operations in China, ... Rule 12b-25 of the Securities Exchange Act of 1934, as amended, ... Report on Form 10-Q for the second quarter ended June 30, ...
... , Visit by Lung Cancer ... , WASHINGTON, Aug. 14 /PRNewswire-USNewswire/ -- Today, Lung ... has signed on as a cosponsor of a bill to establish the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO ) , , ...
... effective with few side effects, study finds , FRIDAY, ... called Levadex is an effective treatment for migraines, according ... trial, conducted at the Jefferson Headache Center at Thomas ... who took the drug had greater relief from symptoms ...
... , WASHINGTON, Aug. 14 The Sixth ... of an Ohio law strictly regulating the provision of the dangerous ... CEO and President of Americans United for Life, stated, "This is ... providers have readily admitted that they administer RU-486 in violation of ...
Cached Medicine News:Health News:Operation Rescue: Wesley Medical Center Promises To Keep Carhart, Abortions Out 2Health News:Nephros Reports 2009 Second Quarter Financial Results 2Health News:Nephros Reports 2009 Second Quarter Financial Results 3Health News:Nephros Reports 2009 Second Quarter Financial Results 4Health News:Nephros Reports 2009 Second Quarter Financial Results 5Health News:AMDL Inc. Files Notification of Late Filing for Form 10-Q 2Health News:Senator Ben Nelson (D-NE) Joins as Co-Sponsor of Lung Cancer Mortality Reduction Act 2Health News:Senator Ben Nelson (D-NE) Joins as Co-Sponsor of Lung Cancer Mortality Reduction Act 3Health News:Americans United for Life Applauds Decision Protecting Women From Dangers of RU-486 2
...
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
It is lightweight and portable headlight option for office exam room. It offers complete comfort and portability....
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
Medicine Products: